Yuval Sagiv
Director Técnico/Científico/I+D en VIDAC PHARMA HOLDING PLC .
Perfil
Yuval Sagiv is currently the Chief Technology Officer at Vidac Pharma Holding Plc.
Previously, he worked as the Director of Preclinical & New Products at Kamada Ltd., Head of Preclinical Development at HealOr Ltd., and Vice President of Research & Development at Nanocarry Therapeutics Ltd.
Sagiv holds a doctorate degree from the Weizmann Institute of Science.
Cargos activos de Yuval Sagiv
Empresas | Cargo | Inicio |
---|---|---|
VIDAC PHARMA HOLDING PLC | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Yuval Sagiv.
Empresas | Cargo | Fin |
---|---|---|
Nanocarry Therapeutics Ltd.
Nanocarry Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation. | Director Técnico/Científico/I+D | - |
KAMADA LTD. | Corporate Officer/Principal | - |
HealOr Ltd.
HealOr Ltd. Pharmaceuticals: MajorHealth Technology HealOr Ltd. develops and commercializes proprietary biochemical regulatory therapeutics impacting skin cells properties for the purpose of treating various skin pathologies. Its leading drug, HO/03/03, is currently undergoing Phase II/III clinical trials in the United States and India. The company is also establishing a first-in-class therapeutic pipeline for additional skin pathologies such as chronic and acute wounds, dry skin, acne, psoriasis, and others. HealOr was founded by Tamar Tennenbaum in 2002 and is headquartered in Rechovot, Israel. | Corporate Officer/Principal | - |
Formación de Yuval Sagiv.
Weizmann Institute of Science | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
KAMADA LTD. | Health Technology |
VIDAC PHARMA HOLDING PLC | Health Technology |
Empresas privadas | 2 |
---|---|
HealOr Ltd.
HealOr Ltd. Pharmaceuticals: MajorHealth Technology HealOr Ltd. develops and commercializes proprietary biochemical regulatory therapeutics impacting skin cells properties for the purpose of treating various skin pathologies. Its leading drug, HO/03/03, is currently undergoing Phase II/III clinical trials in the United States and India. The company is also establishing a first-in-class therapeutic pipeline for additional skin pathologies such as chronic and acute wounds, dry skin, acne, psoriasis, and others. HealOr was founded by Tamar Tennenbaum in 2002 and is headquartered in Rechovot, Israel. | Health Technology |
Nanocarry Therapeutics Ltd.
Nanocarry Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation. | Commercial Services |
- Bolsa de valores
- Insiders
- Yuval Sagiv